Emerging research indicates that interleukin-17 (IL-17), a cytokine with pro-inflammatory properties, plays a critical role in various stages of lung cancer, including initiation, growth, invasion, metastasis, angiogenesis, lymphangiogenesis, and treatment resistance. This evidence concerns the gene IL17A and lung cancer.